Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 15/20 | 0.56 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523184 | 0.90 | NTSR1 (0.60) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL12523185 | 0.89 | NTSR1 (0.58) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL12523183 | 0.88 | NTSR1 (0.62) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL30686901 | 0.84 | NTSR1 (0.72) | NTSR1NTSR2SORT1 | |
| SCHEMBL19682065 | 0.83 | NTSR1 (0.58) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL25957562 | 0.82 | NTSR1 (0.67) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL19682203 | 0.80 | NTSR1 (0.56) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL30038817 | 0.80 | NTSR1 (0.63) | NTSR1NTSR2SORT1 | |
| SCHEMBL30943511 | 0.79 | NMUR2 (0.58) | NTSR1NMUR2NMUR1NTSR2SORT1 | |
| SCHEMBL19682089 | 0.79 | NTSR1 (0.55) | NTSR1NMUR2NMUR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296226-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-8476221-B2 | Methods and compositions for the treatment of metabolic disorders | HALIMED PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120238490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296226-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, FABP3, NTSR1 | NTSR1 3/4885NMUR2 478/4885NMUR1 450/4885 |
| US-20120238490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, FABP3, NTSR1 | NTSR1 3/4885NMUR2 478/4885NMUR1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.